MedTrace Logo

of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve

NCT06405204 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-05-08

No results posted yet for this study

Summary

To evaluate the role of Myo-inositol, melatonin and co-enzyme Q10 on ovarian reserve parameters and ICSI outcome in poor ovarian responder

Conditions

  • IVF

Interventions

DRUG

Myoinositol

an enzymatic isoform of inositol and belongs to the vitamin B complex family

DRUG

Co-Enzyme Q10

a lipid-soluble quinone, acting as an effective antioxidant,

DRUG

Melatonin

an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant

DRUG

Folic acid

control

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Sara A Salem, MD · Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06405204 on ClinicalTrials.gov